FACTORS RELEVANT TO PREVENTING EMBOLIC STROKE IN PATIENTS WITH NONRHEUMATIC ATRIAL-FIBRILLATION

被引:13
作者
FLEGEL, KM [1 ]
HUTCHINSON, TA [1 ]
GROOME, PA [1 ]
TOUSIGNANT, P [1 ]
机构
[1] MCGILL UNIV,ROYAL VICTORIA HOSP,DEPT MED,DIV CLIN EPIDEMIOL,MONTREAL H3A 1A1,QUEBEC,CANADA
关键词
STROKE; ATRIAL FIBRILLATION; CEREBRAL EMBOLISM; PREVENTING STROKE; DECISION-ANALYSIS;
D O I
10.1016/0895-4356(91)90219-Y
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Whether or not to treat patients with non-rheumatic atrial fibrillation with anticoagulants to prevent embolic stroke is a dilemma for physicians. If randomized trials, currently underway, demonstrate a beneficial effect, the dilemma will not be solved because not all of the relevant factors can be addressed by trials. We used current knowledge about non-rheumatic atrial fibrillation and a method of obtaining patient-derived weights for avoiding stroke from eight medically trained subjects, to determine the overall benefit of anticoagulants and to see what factors were relevant and what effect each might have in deciding whether to use anticoagulant therapy. Using standard assumptions, anticoagulants gave an expected benefit for all subjects. The expected benefit (expressed in terms of lives per 1000 saved due to anticoagulants) varied between 5.4 and 46.7. This benefit remained for all subjects when we did a sensitivity analysis for different rates of stroke prevented by anticoagulants and different rates of intracranial hemorrhage caused by anticoagulants. When we used different baseline rates of stroke and different impacts of major hemorrhagic complications the benefit disappeared for 3 and 4 subjects respectively. We found the factors that were most crucial to the decision will not be included in randomized trials: the weight that an individual would place on avoiding embolic stroke vs the risk of intracranial bleeding from anticoagulant therapy; and the rate of embolic stroke that could be expected for the subject at risk. Factors which will be measured in randomized trials, will change results less substantially: the increased risk of major hemorrhages; the proportion of strokes that could be prevented by treatment; the increase in risk of intracranial hemorrhage. This method of analysis suggests that for most patients anticoagulants are beneficial and that the most important factor in determining this result is the value that subjects put on different outcomes.
引用
收藏
页码:551 / 560
页数:10
相关论文
共 20 条
[1]   RISK-FACTORS FOR THROMBOEMBOLIC STROKE IN ELDERLY PATIENTS WITH CHRONIC ATRIAL-FIBRILLATION [J].
ARONOW, WS ;
GUTSTEIN, H ;
HSIEH, FY .
AMERICAN JOURNAL OF CARDIOLOGY, 1989, 63 (05) :366-367
[2]   ANTITHROMBOTIC THERAPY IN ATRIAL-FIBRILLATION [J].
DUNN, M ;
ALEXANDER, J ;
DESILVA, R ;
HILDNER, F .
CHEST, 1986, 89 (02) :S68-S74
[3]  
FLEGEL KM, 1987, LANCET, V1, P526
[4]   RISK-FACTORS FOR STROKE AND OTHER EMBOLIC EVENTS IN PATIENTS WITH NONRHEUMATIC ATRIAL-FIBRILLATION [J].
FLEGEL, KM ;
HANLEY, J .
STROKE, 1989, 20 (08) :1000-1004
[5]   OPTIMAL THERAPEUTIC RANGE FOR ORAL ANTICOAGULANTS [J].
HIRSH, J ;
POLLER, L ;
DEYKIN, D ;
LEVINE, M ;
DALEN, JE .
CHEST, 1989, 95 (02) :S5-S11
[6]   EPIDEMIOLOGIC FEATURES OF CHRONIC ATRIAL-FIBRILLATION - THE FRAMINGHAM-STUDY [J].
KANNEL, WB ;
ABBOTT, RD ;
SAVAGE, DD ;
MCNAMARA, PM .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (17) :1018-1022
[7]   ATRIAL-FIBRILLATION, STROKE AND ANTICOAGULATION - WHAT IS TO BE DONE [J].
KITCHENS, JM ;
FLEGEL, KM .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1986, 1 (02) :126-129
[8]   HEMORRHAGIC COMPLICATIONS OF LONG-TERM ANTICOAGULANT-THERAPY [J].
LEVINE, MN ;
RASKOB, G ;
HIRSH, J .
CHEST, 1986, 89 (02) :S16-S25
[9]  
Lindley D. V., 1985, MAKING DECISIONS
[10]   RISK-FACTORS FOR THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL-FIBRILLATION - THE COPENHAGEN AFASAK STUDY [J].
PETERSEN, P ;
KASTRUP, J ;
HELWEGLARSEN, S ;
BOYSEN, G ;
GODTFREDSEN, J .
ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (04) :819-821